Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open, Randomized Controlled, Multicenter, Exploratory Clinical Study of NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX for Conversion Therapy for Locally Advanced Pancreatic Cancer

NCT06669078 is registered in ClinicalTrials.gov with The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School as lead sponsor.

NCT NCT06669078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06669078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open, Randomized Controlled, Multicenter, Exploratory Clinical Study of NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX for Conversion Therapy for Locally Advanced Pancreatic Cancer
Lead sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 30, 2024
Completion date
October 15, 2027
Enrollment
120 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic cancer